Phone Icon

Current Active Cancer Care Clinical Trials


Protocol # Sponsor Title
14J-MC-HHBB Eli Lilly Phase 1 Exploratory Study of Patients with Alterations in the Hedgehog (hh)/Smoothened (Smo) Pathway
391101 Baxter Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
3V2640-CLIN-002 3-V Biosciences A Phase 1 study of the pill TVB-2640 in patients with any type of solid tumor.
673-301 BioMarin A Study Evaluating BMN 673, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation
ADU-CL-04 Aduro Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting (ECLIPSE)
AG120-C-002 Agios Study of Orally Adminstered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
AG221-C-003 Celgene Study of Orally Administered AG-221 in individuals With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Aldoxorubcin-P1-MTD-03 CytRx A Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ARQ-087-101 ArQule Phase 1, dose escalation study of oral ARQ 087 for patients with advanced solid tumors.
ARQ-092-101 ArQule Phase 1 Study of ARQ 092 in patients with Advanced Solid Tumors and Recurrent Malignant Lymphoma
CC-486 CAGEN 001 Celgene A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors
CLC-101 Cleave Biosciences, Inc. A Phase 1 Study Evaluating the Safety of Orally Administered CB-5083 in Patients With Advanced Solid Tumors
DS6051-A-U101 Daiichi Phase I first in human study of DS-6051B; which is an oral ROS1 and NTRK inhibitor for individuals with advanced solid tumors.
EC1169-01 Endocyte A Phase 1 Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin conjugate EC1169 in Patients with recurrent metastatic, castration-resistant prostate cancer (mCRPC).
EC1456-01 Endocyte Folic Acid-Tubulysin conjugate EC1456 in patients with advanced solid tumors
EMD 100070-001 EMD Serono A Phase I, investigate the safety of MSB0010718C in subjects with metastatic or locally advanced solid tumors.
GS-US-370-1369 Gilead A Phase 1b Study Evaluating Momelotinib Combined with Capecitabine and Oxaliplatin in Subjects with Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
INCB 18424-267 Incyte A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
INCB 39110-116 Incyte Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
M14-011 Abbvie A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
M14-237 Abbvie A Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
MINNELIDE 001 Minneamrita Study of Minnelide™ in Patients With Advanced GI Tumors
MK3475-028-00 Merck Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
MM-398-01-01-02 Merimack A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages
MRX34-101 MiRNA A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension
NA 00090282 SU2C An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy after Induction Chemotherapy in Subjects with Metastatic Pancreatic Adenocarcinoma
PCRT 12-001 Seena Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
PLX119-01 Plexxikon Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors
PMT4979g Genentech A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
PR-20-5006-C Tesaro A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
SM04755-ONC-01 Samumed A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
SU2C-005 SU2C-005 A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
SU2C-007 SU2C 007 A Pharmacodynamic study of the Nab-Paclitaxel/Gemcitabine combo given weekly 3x as induction therapy followed by maintenance every 2 weeks in patients with metastatic pancreatic cancer
TKM-PLK1-001 Tekmira A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
VS-5584-101 Verastem Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma